This article proposes a hybrid orthomolecular protocol aimed at cancer treatment, focusing on targeting mitochondrial dysfunction in cancer cells. It combines traditional cancer therapies with mitochondrial-targeted treatments, such as antioxidants, to disrupt the altered energy metabolism of cancer cells and improve therapy effectiveness. In vitro and animal studies suggest that
